Coriolan Lebreton
A5023971145- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Reproductive System and Pregnancy
- Cancer Genomics and Diagnostics
- Gestational Trophoblastic Disease Studies
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- DNA Repair Mechanisms
- Uterine Myomas and Treatments
- Sarcoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Toxin Mechanisms and Immunotoxins
- Economic and Financial Impacts of Cancer
- Intraperitoneal and Appendiceal Malignancies
- Monoclonal and Polyclonal Antibodies Research
Institut Bergonié
2018-2025
AstraZeneca (France)
2025
Inserm
2023-2024
Intergroupe Francophone de Cancérologie Thoracique
2024
Université de Bordeaux
2023
Centre Léon Bérard
2018-2022
Institut de Cancérologie de l'Ouest
2018
Hospital San Pedro de Alcántara
2018
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), placebo-controlled double-blinded randomized phase III trial, enrolled patients recurrent epithelial OC, one to two previous chemotherapy lines, PFI Eligible were randomly...
In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (HRD)-positive tumors, irrespective of clinical risk. Subsequently, clinically meaningful improvement overall was reported plus HRD-positive subgroup. We report updated by risk HRD status. Patients response after first-line platinum-based chemotherapy...
5550 Background: In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), maintenance ola (a PARP inhibitor) + bevacizumab (bev) led to prolonged progression-free and overall survival vs placebo (pbo) bev in AOC pts, specifically those with homologous recombination-deficient (HRD+) tumors (Ray-Coquard et al. ESMO 2022, LBA29). Here, we explore efficacy of subsequent chemotherapy (CT) pts after progression on first-line (1L) treatment PAOLA-1. Methods: The CT was explored by analyzing median time from...
Primary ovarian leiomyosarcomas are exceptionally rare, constituting less than 1% of tumors, and they typically have a poor prognosis. The available data on the management these tumors sparse, with limited publications mainly comprising small retrospective series that include multiple histologic types. aim is to evaluate clinical, surgical, pathologic characteristics clinical outcome patient affected by primary leiomyosarcomas. Using national database (NetSarc), we conducted study outcomes...
Abstract Background: Malignant ovarian cancer (OC) ascites are increasingly recognized to play a prominent role in tumorigenesis and progression, via complex processes of interactions between tumor cells their surrounding environment, including immune cells. Thus, the characterization metabolic composition OC evaluation biological effects on critical for understanding how ascitic milieu influences behavior response what extent components involved. Methods: Ascites samples were collected from...
En France, le durvalumab est accessible via AAP/CPC/indications remboursées notamment dans cancer du poumon non à petites cellules localement-avancé (CBNPC-LA, 2018), au stade étendu (CBPC-SE, 2020), des voies biliaires (CVB, 2022) et carcinome hépatocellulaire (CHC, 2023). Le PMSI, dépourvu d'informations sur statut moléculaire cancer, a nécessité développement d'algorithmes pour identifier les patients traités. Nous avons comparé leurs caractéristiques celles essais cliniques...
Abstract Background: Gynecologic carcinosarcomas (CS) are highly aggressive/rare tumors. Most patients relapse after first-line therapies and responses to systemic therapy remain low. ROCSAN (NCT03651206) is a multicentric randomized phase II evaluating dostarlimab (anti-PD1) in combination with niraparib (PARPi) compared standard of care the treatment metastatic/recurrent (R/M) CS. Objective: Mandatory tumor tissue archival from naïve initial disease (ND) & baseline biopsies at were...
To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer.
Use of first-line PARP inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy first subsequent (FST) patients experiencing disease progression setting important to optimize post-progression treatments. We evaluated FST from PAOLA-1/ENGOT-ov25 (NCT02477644) who received olaparib maintenance.
<h3>Introduction/Background</h3> UTOLA assessed the efficacy of Parp-inhibitor for advanced/M+ EC pts without progression after 1st line platinum CT and to analyse in some molecular subgroups. <h3>Methodology</h3> is a 2/1 randomized, double-blind, placebo controlled, phase IIb trial, comparing olaparib maintenance (ola, 300 mg po BID) vs (pl) until or intolerance with stratification on P53, MMR status, response previous CT. Primary endpoint was PFS ITT. Main secondary endpoints were...
The aim of this study was to evaluate the incidence and predictive factors Pelvic Insufficiency Fractures (PIFs) occurring after Intensity Modulated Radiation Therapy (IMRT) combined with chemotherapy for locally advanced cervical cancer (CC).Medical records patients receiving radio-chemotherapy IMRT between 2010 2020 CC were reviewed. PIFs detected during follow-up on pelvic Magnetic Resonance Imaging (MRI) or Computed Tomography (CT). cumulative rate its confidence interval calculated at 2...
<h3>Introduction/Background</h3> In PAOLA-1/ENGOT-ov25 (NCT02477644), maintenance PARP inhibitor (PARPi) olaparib+bevacizumab improved progression-free survival (PFS) in patients with homologous recombination-deficient (HRD+) advanced ovarian cancer (Ray-Coquard. NEJM 2019;381:2416–28). Post-hoc analysis showed the efficacy of subsequent chemotherapy at relapse was reduced who progressed during versus after olaparib treatment (Harter. Presented ASCO 2023). OReO/ENGOT-ov38 trial...
<h3>Introduction/Background</h3> Standard therapy for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months includes PARPi maintenance if disease responds to platinum-based chemotherapy. ANITA (NCT03598270) evaluated combining atezolizumab chemotherapy and in this population. <h3>Methodology</h3> Eligible patients had measurable high-grade serous, endometrioid or undifferentiated rOC, ≤2 prior lines of (most recent including platinum) TFIp months. Prior rOC and/or...
The aim of this study was to investigate the association co-medication with metformin, a statin, or beta blocker survival in patients primary ovarian cancer. Individual data from three phase III, randomized controlled trials (AGO-OVAR 11, AGO-OVAR 12, and 16) one II trial 15) were pooled analyzed. Patients classified as ever user if specific documented at least once during trial, compared never users controls. Association co-medications outcomes adjusted for potential confounders (age,...
In the PAOLA-1/ENGOT-ov25 trial, adding maintenance ola to bev improved progression-free survival in homologous recombination deficiency-positive (HRD+; tumour BRCA1/2 mutation [tBRCAm] and/or genomic instability) pts with newly diagnosed AOC at higher and lower risk of progression by disease stage surgical status. Greatest benefits were seen lower-risk (Harter et al. Gynecol Oncol 2022). Here, we analysed 5-y OS according clinical HRD Pts response after first-line platinum-based...
11550 Background: It is crucial that targeted therapies are also studied in senior patients to establish predictive factors of severe toxicity. Methods: The PRETOXE study includes 3 multicentric independent cohorts ≥70 years old with advanced solid tumor (2 retrospectives and one prospective) treated a tyrosine/threonine kinase inhibitor (TKI) as per drug label. Data on clinical biological characteristics the patient, disease treatment were centrally collected at beginning treatment. Primary...